Evidence map›Paper›PMID 40415386›Full record

ArticleJournal of chemical information and modeling2025

Active Learning-Guided Hit Optimization for the Leucine-Rich Repeat Kinase 2 WDR Domain Based on In Silico Ligand-Binding Affinities.

Filipp Gusev, Evgeny Gutkin, Francesco Gentile, Fuqiang Ban, S Benjamin Koby, Fengling Li, Irene Chau, Suzanne Ackloo, Cheryl H Arrowsmith, Albina Bolotokova and 14 more

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Filipp GusevDepartment of Chemistry, Mellon College of Science, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, United States.ORCID 0000-0002-1167-345X
Evgeny GutkinDepartment of Chemistry, Mellon College of Science, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, United States.ORCID 0000-0003-4522-6049
Francesco GentileDepartment of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, Ontario K1N 6N5, Canada.
Fuqiang BanVancouver Prostate Centre, The University of British Columbia, Vancouver, British Columbia V6H 3Z6, Canada.
S Benjamin KobyDepartment of Chemistry, Mellon College of Science, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, United States.ORCID 0009-0007-6643-7271
Fengling LiStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Irene ChauStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Suzanne AcklooStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.ORCID 0000-0002-9696-1839
Cheryl H ArrowsmithStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.ORCID 0000-0002-4971-3250
Albina BolotokovaStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Pegah GhiabiStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Elisa GibsonStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.ORCID 0000-0002-7112-337X
Levon HalabelianStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.ORCID 0000-0003-4361-3619
Scott HoulistonPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2M9, Canada.
Rachel J HardingStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.ORCID 0000-0002-1134-391X
Ashley HutchinsonStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Peter LoppnauStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Sumera PerveenStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Almagul SeitovaStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Hong ZengStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
Matthieu SchapiraStructural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.ORCID 0000-0002-1047-3309
Artem CherkasovVancouver Prostate Centre, The University of British Columbia, Vancouver, British Columbia V6H 3Z6, Canada.ORCID 0000-0002-1599-1439
Olexandr IsayevDepartment of Chemistry, Mellon College of Science, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, United States.ORCID 0000-0001-7581-8497
Maria G KurnikovaDepartment of Chemistry, Mellon College of Science, Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, United States.ORCID 0000-0002-8010-8374

Funding

Free energy-based active learning for ligand off-target and multitarget activityF31CA290946 · NCI · CARNEGIE-MELLON UNIVERSITY · PI Samuel Benjamin Koby · 2025 to 2026
$100k
NCI NIH HHS F31 CA290946
6 · The paper itself

Abstract

The leucine-rich repeat kinase 2 (LRRK2) is the most mutated gene in familial Parkinson's disease, and its mutations lead to pathogenic hallmarks of the disease. The LRRK2 WDR domain is an understudied drug target for Parkinson's disease, with no known inhibitors prior to the first phase of the Critical Assessment of Computational Hit-Finding Experiments (CACHE) Challenge. A unique advantage of the CACHE Challenge is that the predicted molecules are experimentally validated in-house. Here, we report the design and experimental confirmation of LRRK2 WDR inhibitor molecules. We used an active learning (AL) machine learning (ML) workflow based on optimized free-energy molecular dynamics (MD) simulations utilizing the thermodynamic integration (TI) framework to expand a chemical series around two of our previously confirmed hit molecules. We identified 8 experimentally verified novel inhibitors out of 35 experimentally tested (23% hit rate). These results demonstrate the efficacy of our free-energy-based active learning workflow to explore large chemical spaces quickly and efficiently while minimizing the number and length of expensive simulations. This workflow is widely applicable to screening any chemical space for small-molecule analogs with increased affinity, subject to the general constraints of RBFE calculations. The mean absolute error of the TI MD calculations was 2.69 kcal/mol, with respect to the measured

Indexed as

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2Machine LearningProtein Kinase InhibitorsHumansLigandsMolecular Dynamics SimulationProtein BindingProtein DomainsThermodynamicsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LigandsLRRK2 protein, humanProtein Kinase Inhibitors

Identifiers

PMID40415386
PMCPMC12152950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.